# Czechia Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Czechia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Czechia (CZE)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $1.9B
- Products: 44
- Buyer markets: 27
- Average CAGR: +15.0%
- Global sector size: $791.9B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $298.1B | $1.4B | $111.3B | +22.0% | 19 | +0.6% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $168.4B | $111.5M | $69.3B | +14.6% | 17 | +0.1% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $30.7B | $259.6K | $49.2B | -9.6% | 5 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $19.8B | $3.2K | $28.4B | -9.1% | 2 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $19.4B | $407.5K | $23.0B | +7.6% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $26.3B | $41.0M | $22.1B | +11.5% | 6 | +0.2% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $197.8K | $16.8B | +7.0% | 3 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.1B | $4.4M | $15.0B | +3.4% | 6 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $26.4B | $75.8M | $14.9B | -5.3% | 5 | +0.3% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $24.4B | $129.7M | $14.6B | +28.3% | 7 | +0.8% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $8.0B | $7.7K | $12.3B | -3.0% | 5 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $12.6B | $57.7M | $10.7B | +56.6% | 4 | +0.4% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $6.8B | $108.3K | $9.6B | +14.2% | 2 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $2.7M | $7.4B | +7.0% | 2 | +0.0% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $2.4 | $6.7B | -69.8% | 1 | +0.0% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $10.1B | $424.5K | $6.4B | +12.1% | 3 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $12.0M | $6.3B | +15.5% | 3 | +0.1% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $4.7B | $2.2M | $6.1B | -2.1% | 3 | +0.1% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $8.0M | $5.9B | +29.2% | 2 | +0.1% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $4.2B | $10.6K | $4.8B | -7.7% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $31.7M | $4.0B | +26.0% | 2 | +0.8% |
| HS 283691 - Carbonates: lithium carbonate | $2.5B | $3.1K | $3.8B | +118.9% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $231.2K | $3.3B | +15.5% | 2 | +0.0% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $1.9B | $1.0K | $2.7B | -24.3% | 1 | +0.0% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $241.9 | $2.4B | -9.3% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $3.6K | $2.4B | +37.2% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.4B | $225.0 | $2.3B | +11.8% | 1 | +0.0% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $3.4K | $2.2B | +34.2% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $18.9M | $2.1B | +22.0% | 1 | +0.6% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $3.4K | $2.0B | -8.1% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $99.8K | $2.0B | +4.7% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $0.6 | $1.8B | -34.7% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $2.9K | $1.8B | +14.6% | 1 | +0.0% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $57.1K | $1.7B | +4.4% | 1 | +0.0% |
| HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $5.9K | $1.5B | +56.6% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $97.3K | $1.4B | +5.2% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $602.7 | $1.4B | +14.3% | 1 | +0.0% |
| HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $1.0B | $3.3K | $1.4B | +18.3% | 1 | +0.0% |
| HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $4.5K | $1.3B | -18.4% | 1 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $5.6K | $1.3B | +24.4% | 1 | +0.0% |
| HS 284330 - Gold compounds | $877.8M | $608.3 | $1.2B | +12.9% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $36.2K | $1.2B | +8.2% | 1 | +0.0% |
| HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $655.8M | $4.1K | $1.2B | +280.7% | 1 | +0.0% |
| HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $926.2 | $1.2B | +8.1% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $154.1B calculated opportunity across 21 products.
- China (CHN): $41.0B calculated opportunity across 15 products.
- Slovenia (SVN): $38.9B calculated opportunity across 6 products.
- Germany (DEU): $38.2B calculated opportunity across 12 products.
- Switzerland, Liechtenstein (CHE): $36.5B calculated opportunity across 4 products.
- Belgium (BEL): $29.4B calculated opportunity across 5 products.
- Italy (ITA): $23.8B calculated opportunity across 4 products.
- Netherlands (NLD): $19.5B calculated opportunity across 5 products.
- United Kingdom (GBR): $11.0B calculated opportunity across 5 products.
- Japan (JPN): $10.9B calculated opportunity across 4 products.
- Canada (CAN): $9.8B calculated opportunity across 5 products.
- France (FRA): $9.2B calculated opportunity across 4 products.

## Growth stars

- HS 293319: +280.7% average CAGR, $1.2B calculated opportunity.
- HS 283691: +118.9% average CAGR, $3.8B calculated opportunity.
- HS 382600: +56.6% average CAGR, $10.7B calculated opportunity.
- HS 284690: +56.6% average CAGR, $1.5B calculated opportunity.
- HS 285390: +37.2% average CAGR, $2.4B calculated opportunity.
- HS 290531: +34.2% average CAGR, $2.2B calculated opportunity.
- HS 330499: +29.2% average CAGR, $5.9B calculated opportunity.
- HS 300439: +28.3% average CAGR, $14.6B calculated opportunity.
- HS 330300: +26.0% average CAGR, $4.0B calculated opportunity.
- HS 290110: +24.4% average CAGR, $1.3B calculated opportunity.

## Diversification opportunities

- HS 300490: 19 buyer markets, $111.3B calculated opportunity.
- HS 300215: 17 buyer markets, $69.3B calculated opportunity.
- HS 300439: 7 buyer markets, $14.6B calculated opportunity.
- HS 300220: 6 buyer markets, $22.1B calculated opportunity.
- HS 382499: 6 buyer markets, $15.0B calculated opportunity.
- HS 293719: 5 buyer markets, $49.2B calculated opportunity.
- HS 300212: 5 buyer markets, $14.9B calculated opportunity.
- HS 284190: 5 buyer markets, $12.3B calculated opportunity.
- HS 382600: 4 buyer markets, $10.7B calculated opportunity.
- HS 293359: 3 buyer markets, $23.0B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.